ARTICLE | Clinical News
MG98: Phase II
July 15, 2002 7:00 AM UTC
In a North American Phase II trial, twice-weekly MG98 failed to give an objective clinical response in RCC patients. BBG has European rights to MG98 under a February deal with MethylGene. MOGN has U.S...